## Supporting Information

## Synthesis of Novel Unnatural $\alpha$-Amino Acid (UAAs) Containing 7-Hydroxy-2, 2-DimethylChroman using Isoxazole as Linker

K. Raghavulu ${ }^{\text {a, b }}$, Ramakrishna Gudipati ${ }^{\text {a, b }}$, K. Basavaiah ${ }^{\text {b }}$, Chidananda Swamy Rumalla ${ }^{\text {a }}$ SatyanarayanaYennam ${ }^{\text {a }}$ \& ManoranjanBehera*a

${ }^{\text {a }}$ Chemistry Services, Aragen Life Sciences (Formerly known as GVK Biosciences), Survey No’s: 125 (part) \& 126, IDA Mallapur, Hyderabad-500076, Telangana State, India
${ }^{\text {b }}$ Department of Inorganic\& Analytical Chemistry, Andhra University, Waltair Junction, Visakhapatnam, Andhra Pradesh, 530003, India

E-mail:Manoranjan.behera@ gvkbio.com; Tel: +040 67483507

## Contents

1. General information
2. Spectral data

## General Information:

All the chemicals were commercially available and procured from companies like Aldrich, Spectrochem (India), S. D. Fine (India), combi-block, fluorochem, matrix and Avra (India) and have been carried forward without further purification. Solvents used in the present study are dried before prior use whenever required. Precoated TLC silica gel plates (Kieselgel 60 F254, Merck) were used for monitoring reactions. Purification was performed by column chromatography using silica gel (Particle size 60-120 mesh, Merck). Melting points were determined in open capillary tubes on cintex melting point apparatus and are uncorrected. IR ( KBr ) spectra were recorded on Perkin-Elmer FT/IR4000 using ATR (vmax in cm-1) in the frequency range of 600-4000 cm-1. 1H NMR and 13C NMR spectra were recorded in $\mathrm{CDCl}_{3} / \mathrm{DMSO}-d 6$ on a Bruker DRX-400 ( 400 MHz FT NMR). Chemical shifts are presented in $\delta$ ppm employing TMS as internal reference. Splitting patterns were reported as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad.


Experimental procedure for the preparation of ethyl 3-(3-(7-hydroxy-2,2-dimethylchroman-6-yl)isoxazol-5-yl)-2-pivalamidopropanoate (6a): To a stirred solution of compound 8a ( 70 mg , $0.131 \mathrm{mmol})$ in ethanol $(10 \mathrm{ml}), 10 \% \mathrm{Pd} / \mathrm{C}(30 \mathrm{mg})$ was added and stirred at room temperature for 24 h under hydrogen atmosphere ( 30 psi ). The progress of the reaction was monitored by TLC analysis ( $20 \%$ ethyl acetate/pet ether). After completion of the reaction, the reaction mixture was filtered through celite bed and washed the celite bed with ethanol twice ( $2 \times 10 \mathrm{ml}$ ). Combined organic layers were concentrated under reduced pressure to give the crude compound which was purified by Prep TLC to give compound 11 ( $50 \mathrm{mg}, 86 \%$ ); MR: $155-158^{\circ} \mathrm{C}$; IR ( $\mathrm{KBr}, \mathrm{cm}^{-1}$ ): 3380, 2973.4, 2932, 2867.3, $1743,1644,1520,1450,1376,1288,1205,1152,1118,1022,955,879,867,772,621 .{ }^{1} \mathrm{H}$ NMR (500 $\mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=9.22(\mathrm{~s}, 1 \mathrm{H},-\mathrm{OH}), 7.09(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.46(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.39-6.37(\mathrm{~d}, J=7 \mathrm{~Hz}$, $1 \mathrm{H},-\mathrm{NH}$ ), $6.34(\mathrm{~s}, 1 \mathrm{H}$, isoxazole-H), 4.89-4.86 ( $\mathrm{q}, 1 \mathrm{H}$, chiral-H), 4.30-4.22 (q, 2H, -OCH2), 3.50-3.33 $\left(\mathrm{m}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 2.75-2.72\left(\mathrm{t}, J=13.5 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 1.82-1.79\left(\mathrm{t}, J=13.5 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right), 1.34(\mathrm{~s}$, $\left.6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right), 1.32-1.30\left(\mathrm{t}, \mathrm{J}=13 \mathrm{~Hz}, 3 \mathrm{H},-\mathrm{CH}_{3}\right), 1.20\left(\mathrm{~s}, 9 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{3}\right) ;{ }^{13} \mathrm{C}$ NMR $\left(500 \mathrm{MH}_{\mathrm{Z}}, \mathrm{CDCl}_{3}\right)$ $=178.50,170.75,167.53,162.54,157.18,156.37,128.67,113.18,106.14,105.11,100.48,75.08$, 62.38, 50.89, 38.90, 32.96, 29.100, 27.51, 27.00, 21.86, 14.24. MS (EI): m/z 445 (M+1, 100); HRMS: calcd for: $\mathrm{C}_{24} \mathrm{H}_{33} \mathrm{~N}_{2} \mathrm{O}_{6}[\mathrm{M}+\mathrm{H}]: 445.2339$; Found: 445.2340.


Ethyl 2-acetamido-3-(3-(7-hydroxy-2,2-dimethylchroman-6-yl)isoxazol-5-yl)propanoate (6b): MR: $76-79^{\circ} \mathrm{C}$; IR (KBr, $\mathrm{cm}^{-1}$ ): 3274.3, 3065, 2980.1, 2930, 2854.7, 1741.8, 1669.4, 1635.7, 1582.6, 1518, 1448.6, 1375.3, 1287.5, 1211.3, 1154.4, 1116.8, 1027.1, 961.5, 879.5, 755.1, 599.8; ${ }^{1} \mathrm{H}$ NMR (400 $\mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=9.20(\mathrm{~s}, 1 \mathrm{H},-\mathrm{OH}), 7.12(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.46(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.37(\mathrm{~s}, 1 \mathrm{H}$, isoxazoleH), 6.26-6.25 (d, $J=7.2 \mathrm{~Hz}, 1 \mathrm{H},-\mathrm{NH}$ ), 4.95-4.90 ( $\mathrm{q}, 1 \mathrm{H}$, chiral-H), 4.30-4.22 (q, 2H, $-\mathrm{OCH}_{2}$ ), 3.48$3.33\left(\mathrm{~m}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 2.76-2.72\left(\mathrm{t}, J=13.6 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 2.04\left(\mathrm{~s}, 3 \mathrm{H},-\mathrm{COCH}_{3}\right), 1.82-1.79(\mathrm{t}, J=$
$\left.13.6 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right), 1.34\left(\mathrm{~s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right), 1.31-1.27\left(\mathrm{t}, J=14 \mathrm{~Hz}, 3 \mathrm{H},-\mathrm{CH}_{3}\right) ;{ }^{13} \mathrm{C}$ NMR ( $100 \mathrm{MH}_{\mathrm{Z}}$, $\left.\mathrm{CDCl}_{3}\right)=170.39,169.94,167.20,162.43,157.05,156.20,128.58,113.03,105.93,104.95,100.42$, $74.93,62.30,50.80,32.80,29.67,29.15,26.83,23.14,21.68,14.08$; MS (ESI): m/z 403 (M+1, 100).


Ethyl 2-((tert-butoxycarbonyl)amino)-3-(3-(7-hydroxy-2,2-dimethylchroman-6-yl) isoxazol-5yl)propanoate ( $6 \boldsymbol{c}$ ): MR: 103-106 ${ }^{\circ} \mathrm{C}$; IR ( $\mathrm{KBr}, \mathrm{cm}^{-1}$ ): 3356.2, 3247.3, 3148.9, 2977.2, 2931.9, 2852.8, $1737.9,1709.9,1638.6,1585.5,1514.1,1450.5,1369.5,1289.4,1222.9,1187.2,1160.2,1017.4$, 962.5, 878.6, 846.7. 792.7, 615.3; ${ }^{1} \mathrm{H}$ NMR ( $500 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=9.23(\mathrm{~s}, 1 \mathrm{H},-\mathrm{OH}), 7.12(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-$ H), $6.46(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.39(\mathrm{~s}, 1 \mathrm{H}$, isoxazole-H), $5.25-5.24(\mathrm{~d}, J=7.5 \mathrm{~Hz}, 1 \mathrm{H},-\mathrm{NH}), 4.68-4.66(\mathrm{~m}$, 1 H , chiral-H), 4.27-4.21 ( $\mathrm{q}, 2 \mathrm{H},-\mathrm{OCH}_{2}$ ), 3.41-3.32 (m, 2H, - $\mathrm{CH}_{2}$ ), 2.75-2.73 (t, $J=13 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}$ ), $1.82-1.80\left(\mathrm{t}, \mathrm{J}=13.5 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right), 1.44\left(\mathrm{~s}, 9 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{3}\right), 1.34\left(\mathrm{~s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right), 1.29-1.26(\mathrm{t}, J=$ $\left.14.5 \mathrm{~Hz}, 3 \mathrm{H},-\mathrm{CH}_{3}\right) ;{ }^{13} \mathrm{C}$ NMR $\left(150 \mathrm{MHz}_{\mathrm{L}}, \mathrm{CDCl}_{3}\right)=170.58,167.38,162.42,156.98,156.22,155.07$, $128.57,112.97,106.03,104.93,100.22,80.41,74.90,62.09,51.97,32.81,29.71,28.24,26.85,21.69$, 14.09; MS (ESI): m/z 461 (M+1, 100).


Experimental procedure for the preparation of ethyl 3-(3-(7-methoxy-2,2-dimethylchroman-6-yl)isoxazol-5-yl)-2-pivalamidopropanoate (7a): To a stirred solution of compound 21 ( $1 \mathrm{~g}, 4.255$ $\mathrm{mmol})$ and compound $19 \mathbf{a}(1.148 \mathrm{~g}, 5.106 \mathrm{mmol})$ in dichloromethane ( 15 ml ), was added triethylamine $(0.888 \mathrm{ml}, 6.382 \mathrm{mmol})$ at $0^{\circ} \mathrm{C}$ and stirred for 10 min then added $10 \%$ aqueous NaOCl solution ( 15 $\mathrm{ml})$ and the reaction mixture was stirred at room temperature for 16 h . The progress of the reaction was monitored by TLC analysis ( $30 \%$ ethyl acetate/pet ether). After completion of the reaction, the reaction mixture was diluted with dichloromethane $(250 \mathrm{ml})$ and washed with water and brine solution.

Organic layer was dried over anhydrous $\mathrm{Na}_{2} \mathrm{SO}_{4}$ and concentrated under reduced pressure to give the crude residue which was charged on silica gel column. The column was eluted with $40 \%$ ethyl acetate/pet ether to give the compound $7 \mathbf{7 a}$ ( $1.5 \mathrm{~g}, 77 \%$ yield) as off white solid.
MR: $121-124^{\circ} \mathrm{C}$; IR ( $\mathrm{KBr}, \mathrm{cm}^{-1}$ ): 3433, 3408, 2976, 2931, 1814, 1741, 1659, 1623, 1601, 1469, 1439, 1363, 1274, 1262, 1199, 1158, 1119, 1065, 1025, 752; ${ }^{1} \mathrm{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=7.60(\mathrm{~s}, 1 \mathrm{H}$, Ar-H), $6.51(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.41(\mathrm{~s}, 1 \mathrm{H}$, isoxazole-H ), $6.38(\mathrm{bs}, 1 \mathrm{H},-\mathrm{NH}), 4.86-4.84(\mathrm{q}, 1 \mathrm{H}$, chiralCH ), 4.30-4.19 (q, 2H, $-\mathrm{OCH}_{2}$ ), $3.79\left(\mathrm{~s}, 3 \mathrm{H},-\mathrm{OCH}_{3}\right), 3.46-3.32\left(\mathrm{~m}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 2.75-2.72(\mathrm{t}, \mathrm{J}=13.2$ $\left.\mathrm{Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 1.82-1.79\left(\mathrm{t}, J=13.6 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right), 1.35\left(\mathrm{~s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right), 1.32-1.28(\mathrm{t}, J=14.4$ $\left.\mathrm{Hz}, 3 \mathrm{H},-\mathrm{CH}_{3}\right), 1.21\left(\mathrm{~s}, 9 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{3}\right) ;{ }^{13} \mathrm{C}$ NMR $\left(400 \mathrm{MH}_{\mathrm{Z}}, \mathrm{CDCl}_{3}\right)=178.19,170.71,166.95,129.88$, $113.39,104.50,100.36,75.06,62.01,55.44,50.92,38.72,32.82,29.00,27.36,26.83,21.48,14.10$; MS (ESI): m/z 459 ( $\mathrm{M}+1,100$ ).


Experimental procedure for the preparation of ethyl 3-(3-(7-(benzyloxy)-2,2-dimethylchroman-6-yl)isoxazol-5-yl)-2-pivalamidopropanoate (8a): To a stirred solution of compound 18 ( 150 mg , 0.482 mmol ) and compound $19 \mathrm{a}(130.2 \mathrm{mg}, 0.578 \mathrm{mmol})$ in dichloromethane ( 10 ml ), was added triethylamine $(0.1 \mathrm{ml}, 0.723 \mathrm{mmol})$ at $0^{\circ} \mathrm{C}$ and stirred for 10 min then added $10 \%$ aqueous NaOCl solution ( 2 ml ) and the reaction mixture was stirred at room temperature for 16 h . The progress of the reaction was monitored by TLC analysis ( $30 \%$ ethyl acetate/pet ether). After completion of the reaction, the reaction mixture was diluted with dichloromethane $(25 \mathrm{ml})$ and washed with water and brine solution. Organic layer was dried over anhydrous $\mathrm{Na}_{2} \mathrm{SO}_{4}$ and concentrated under reduced pressure to give the crude residue which was charged on silica gel column. The column was eluted with $16 \%$ ethyl acetate/pet ether to give the compound $\mathbf{8 a}(160 \mathrm{mg}, 62 \%$ yield) as off white solid.
MR: $129-132^{0} \mathrm{C}$; $\mathrm{IR}\left(\mathrm{KBr}, \mathrm{cm}^{-1}\right): 3364,3176,2968,2925,2864,1748,1666,1606,1515,1463,1383$, 1291, 1191, 1120, 1018, 917, 732, 695, 604; ${ }^{1} \mathrm{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=7.65$ (s, 1H, Ar-H), 7.41$7.30(\mathrm{~m}, 5 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.49(\mathrm{~s}, 1 \mathrm{H}, ~ A r-H), 6.47(\mathrm{~s}, 1 \mathrm{H}$, isoxazole-H), $6.35(\mathrm{~d}, J=7.2 \mathrm{~Hz}, 1 \mathrm{H},-\mathrm{NH}), 5.06$ ( $\mathrm{s}, 2 \mathrm{H}, \mathrm{Bn}-\mathrm{CH}_{2}$ ), 4.84-4.80 ( $\mathrm{q}, 1 \mathrm{H}$, chiral-H ), 4.16-4.10 ( $\mathrm{q}, 2 \mathrm{H},-\mathrm{OCH}_{2}$ ), 3.38-3.27 (m, $2 \mathrm{H},-\mathrm{CH}_{2}$ ), 2.76-2.73 (t, $\left.J=13.2 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 1.81-1.78\left(\mathrm{t}, J=13.2 \mathrm{~Hz}, 2 \mathrm{H}, \operatorname{Ar}-\mathrm{CH}_{2}\right), 1.34\left(\mathrm{~s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right)$, 1.25-1.21 (t, $\left.J=15.2 \mathrm{~Hz}, 3 \mathrm{H},-\mathrm{CH}_{3}\right), 1.15\left(\mathrm{~s}, 9 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{3}\right) ;{ }^{13} \mathrm{C} \mathrm{NMR}\left(400 \mathrm{MH}_{\mathrm{z}}, \mathrm{CDCl}_{3}\right)=178.14$,
$170.59,167.0,159.94,156.47,155.94,136.55,129.96,128.64,128.03,127.31,113.78,109.86$, $104.42,101.53,75.07,70.44,61.88,50.83,38.63,32.76,29.03,27.30,26.80,21.50,14.04$. MS (ESI): m/z $535(\mathrm{M}+1,100)$; HRMS: Calcd for: $\mathrm{C}_{31} \mathrm{H}_{39} \mathrm{~N}_{2} \mathrm{O}_{6}[\mathrm{M}+\mathrm{H}]$ : 535.2808; Found: 535.2820.


Ethyl 2-acetamido-3-(3-(7-(benzyloxy)-2, 2-dimethylchroman-6-yl) isoxazol-5-yl) propanoate (8b): MR: $111-114^{0} \mathrm{C}$; IR ( $\mathrm{KBr}, \mathrm{cm}^{-1}$ ): 3292.6, 3065, 2978.2, 2931.9, 1741.8, 1665.6, 1516.1, 1457.2, $1383.9,1274,1119.7,753.2,698.2 ;{ }^{1} \mathrm{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=7.64(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 7.41-7.34(\mathrm{~m}$, $5 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.49(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.48(\mathrm{~s}, 1 \mathrm{H}$, isoxazole-H$), 6.15-6.13(\mathrm{~d}, J=7.6 \mathrm{~Hz}, 1 \mathrm{H},-\mathrm{NH}), 5.06-$ $5.05\left(\mathrm{~s}, 2 \mathrm{H}, \mathrm{Bn}-\mathrm{CH}_{2}\right), 4.87-4.85\left(\mathrm{~m}, 1 \mathrm{H}\right.$, chiral-H), 4.17-4.12 (q, 2H, $-\mathrm{OCH}_{2}$ ), 3.33-3.31 (m, 2H, $\mathrm{CH}_{2}$ ), 2.77-2.73 (t, $J=16 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}$ ), $1.90\left(\mathrm{~s}, 3 \mathrm{H},-\mathrm{COCH}_{3}\right), 1.82-1.79\left(\mathrm{t}, J=14 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right)$, $1.34\left(\mathrm{~s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right), 1.24-1.20\left(\mathrm{t}, J=14.4 \mathrm{~Hz}, 3 \mathrm{H},-\mathrm{CH}_{3}\right) ;{ }^{13} \mathrm{C}$ NMR $\left(100 \mathrm{MHz}_{\mathrm{z}}, \mathrm{CDCl}_{3}\right)=170.39$, $169.75,166.81,160.01,156.49,155.94,136.56,129.98$, $128.65,128.12,127.48,113.78,109.81$, $104.39,101.46,75.09,75.50,62.00,50.83,32.74,29.21,26.81,23.00,21.50,14.05$; MS (ESI): m/z 493 (M+1, 100).


Ethyl 3-(3-(7-(benzyloxy)-2,2-dimethylchroman-6-yl)isoxazol-5-yl)-2-((tert-butoxycarbonyl)amino) propanoate (8c):MR: 149-152 ${ }^{\circ} \mathrm{C}$; IR ( $\mathrm{KBr}, \mathrm{cm}^{-1}$ ): 3347.6, 2977.2, 2930, 2864.4, 1736.9, 1708, 1600.9, 1519.9, 1457.2, 1384.9, 1290.4, 1220.9, 1167.9, 1116.8, 1060.8, 1019.4, 926.8, 732.9, 696.3; ${ }^{1} \mathrm{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=7.64(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 7.40-7.32(\mathrm{~m}, 5 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.51(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.48(\mathrm{~s}, 1 \mathrm{H}$, isoxazole-H), 5.22-5.20 (d, $J=8 \mathrm{~Hz}, 1 \mathrm{H},-\mathrm{NH}$ ), $5.07\left(\mathrm{~s}, 2 \mathrm{H}, \mathrm{Bn}^{2}-\mathrm{CH}_{2}\right), 4.61-4.59(\mathrm{~m}, 1 \mathrm{H}$, chiral-H), 4.15-4.09 (q, 2H, $-\mathrm{OCH}_{2}$ ), $3.28-3.27\left(\mathrm{~d}, J=4.4 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 2.76-2.73\left(\mathrm{t}, J=13.2 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right)$,
$1.82-1.79\left(\mathrm{t}, J=13.2 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right), 1.42\left(\mathrm{~s}, 9 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{3}\right), 1.34\left(\mathrm{~s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right), 1.22-1.18(\mathrm{t}, J=$ $14.4 \mathrm{~Hz}, 3 \mathrm{H},-\mathrm{CH}_{3}$ ); ${ }^{13} \mathrm{C}$ NMR ( $100 \mathrm{MHz}_{\mathrm{z}}, \mathrm{CDCl}_{3}$ ): $=170.67,166.97,160.0,156.44,155.92,155.06$, $136.58,130.17,129.86,128.78,128.46,128.15,127.83,127.16,113.77,109.98,104.44,104.17$, $101.68,101.43,80.13,75.06,70.48 .70 .13,61.78,52.2,52.06,32.76,29.27,28.27,28.21,26.86$, 26.77, 21.72, 21.51, 14.12. 13.98; MS (ESI): m/z 551 (M+1, 100).


Experimental procedure for the preparation of (7-hydroxy-2, 2-dimethylchromane-6-carbaldehyde) (12): To a stirred solution of compound $\mathbf{1 1}(1 \mathrm{~g}, 5.617 \mathrm{mmol})$ in THF ( 30 ml ), were added $\mathrm{MgCl}_{2}$ ( 802 $\mathrm{mg}, 8.425 \mathrm{mmol}$ ) and triethylamine ( $2.892 \mathrm{ml}, 20.782 \mathrm{mmol}$ ) at RT and stirred for 20 min . Then was added Para formaldehyde $(3.145 \mathrm{~g}, 37.92 \mathrm{mmol})$ and stirred for 1 h at RT followed by reflux for 7 h.The reaction was monitored by TLC analysis ( $10 \%$ ethyl acetate/pet ether). After completion of the reaction, THF was evaporated under reduced pressure and the reaction mixture was diluted with Ethyl acetate ( 100 ml ) and passed through celite bed. Bed was washed with ethyl acetate ( 100 ml ). Combined RM was washed with water ( 100 ml ) and brine solution. Organic layer was dried over anhydrous $\mathrm{Na}_{2} \mathrm{SO}_{4}$ and concentrated under reduced pressure to give the crude residue which was charged on silica gel column. The column was eluted with 5\% ethyl acetate/pet ether to give the compound $\mathbf{1 2}$ ( 810 mg , $70 \%$ yield). ${ }^{1} \mathrm{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta 11.07(\mathrm{~s}, 1 \mathrm{H},-\mathrm{CHO}), 9.66(\mathrm{~s}, 1 \mathrm{H},-\mathrm{OH}), 7.21(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-$ $\mathrm{H}), 6.31(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 2.77-2.73\left(\mathrm{t}, J=13.2 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 1.84-1.81\left(\mathrm{t}, J=13.2 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right)$, 1.36 ( $\left.\mathrm{s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right)$; MS (ESI): m/z 207 (M+1,100).


Experimental procedure for the preparation of 7-(benzyloxy)-2, 2-dimethylchromane-6carbaldehyde (13): To a stirred solution of compound $\mathbf{1 2}$ ( $400 \mathrm{mg}, 1.951 \mathrm{mmol}$ ) in DMF ( 5 ml ), were added $\mathrm{K}_{2} \mathrm{CO}_{3}$ ( $538 \mathrm{mg}, 3.902 \mathrm{mmol}$ ) and Benzyl bromide ( $0.243 \mathrm{ml}, 2.048 \mathrm{mmol}$ ), stirred for 2 h at RT. The reaction was monitored by TLC analysis ( $10 \%$ ethyl acetate/pet ether). After completion of
the reaction, the reaction mixture was diluted with Ethyl acetate ( 100 ml ) and washed with water (100 ml ) and brine solution. Organic layer was dried over anhydrous $\mathrm{Na}_{2} \mathrm{SO}_{4}$ and concentrated under reduced pressure to give the crude residue which was charged on silica gel column. The column was eluted with $8 \%$ ethyl acetate/pet ether to give the compound $\mathbf{1 3}$ ( $550 \mathrm{mg}, 95 \%$ yield): : ${ }^{1} \mathrm{H}$ NMR ( 400 $\mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta 10.36$ ( $\mathrm{s}, 1 \mathrm{H},-\mathrm{CHO}$ ), 7.62 ( $\left.\mathrm{s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}\right), 7.44-7.34$ (m, 5H, Ar-H), 6.42 (s, 1H, ArH), $5.10\left(\mathrm{~s}, 2 \mathrm{H},-\mathrm{OCH}_{2}\right), 2.76-2.72\left(\mathrm{t}, J=13.6 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 1.83-1.79\left(\mathrm{t}, J=13.6 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right)$, 1.35 (s, 6H, -( $\left.\mathrm{CH}_{3}\right)_{2}$ ); MS (ESI): m/z 297 (M+1, 100).


Experimental procedure for the preparation of (7-(benzyloxy)-2,2-dimethylchroman-6-yl)methanol (14): To a stirred solution of compound 13 ( $500 \mathrm{mg}, 1.689 \mathrm{mmol}$ ) in THF ( 10 ml ) was added LAH $\left(128.3 \mathrm{mg}, 3.378 \mathrm{mmol}\left(1 \mathrm{M}\right.\right.$ in THF)) at $0^{\circ} \mathrm{C}$ and stirred for 2 h at RT. The progress of the reaction was monitored by TLC analysis ( $10 \%$ ethyl acetate/pet ether). After completion of the reaction, the reaction mixture was diluted with ethyl acetate $(100 \mathrm{ml})$ and washed with water and brine solution. Organic layer was dried over anhydrous $\mathrm{Na}_{2} \mathrm{SO}_{4}$ and concentrated under reduced pressure to give the crude residue which was charged on silica gel column. The column was eluted with $15 \%$ ethyl acetate/pet ether to give the compound $\mathbf{1 4}(420 \mathrm{mg}, 83 \%$ yield) as off white solid.
${ }^{1} \mathrm{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta 7.40-7.33(\mathrm{~m}, J=29.6 \mathrm{~Hz}, 5 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.96(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.43(\mathrm{~s}, 1 \mathrm{H}$, Ar-H), $5.03\left(\mathrm{~s}, 2 \mathrm{H},-\mathrm{OCH}_{2}\right), 4.63-4.62\left(\mathrm{~d}, J=5.6 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{OCH}_{2}\right), 2.71-2.68(\mathrm{t}, J=13.2 \mathrm{~Hz}, 2 \mathrm{H},-$ $\mathrm{CH}_{2}$ ), $2.15(\mathrm{bs}, 1 \mathrm{H},-\mathrm{OH}), 1.79-1.76\left(\mathrm{t}, J=13.6 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right), 1.32\left(\mathrm{~s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right)$; MS (APCI): m/z 280 ([M-OH] ${ }^{+}, 100$ ).


Experimental procedure for the preparation of (E)-7-(benzyloxy)-2,2-dimethylchroman-6carbaldehyde oxime (18): To a stirred solution of compound 13 ( $400 \mathrm{mg}, 1.35 \mathrm{mmol}$ ) in Methanol: water ( $16: 4 \mathrm{ml}$ ) were added $\mathrm{NH}_{2} \mathrm{OH} . \mathrm{HCl}\left(111.8 \mathrm{mg}, 1.62 \mathrm{mmol}\right.$ ), and $\mathrm{Na}_{2} \mathrm{CO}_{3}$ ( $171 \mathrm{mg}, 1.62 \mathrm{mmol}$ ) and heated at $90^{\circ} \mathrm{C}$ for 1 h . The progress of the reaction was monitored by TLC analysis ( $20 \%$ ethyl
acetate/pet ether). After completion of the reaction, the reaction mixture was concentrated under reduced pressure. Water was added to reaction mixture, white solid was precipitated. Filtered the precipitate and dried under vacuum to give the compound $\mathbf{1 8}$ ( $300 \mathrm{mg}, 71 \%$ yield) as off white solid.; ${ }^{1} \mathrm{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=8.48(\mathrm{~s}, 1 \mathrm{H},-\mathrm{N}=\mathrm{CH}), 7.48(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 7.40-7.32(\mathrm{~m}, 5 \mathrm{H}, \mathrm{Ar}-\mathrm{H})$, 7.03 (s, 1H, -OH), $6.41(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 5.01\left(\mathrm{~s}, 2 \mathrm{H}, \mathrm{Bn}^{2}-\mathrm{CH}_{2}\right), 2.73-2.70\left(\mathrm{t}, J=10.8 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right)$, $1.80-1.77\left(\mathrm{t}, J=13.2 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right), 1.33\left(\mathrm{~s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right) . \mathrm{MS}(\mathrm{ESI}): \mathrm{m} / \mathrm{z} 312(\mathrm{M}+1,100)$.


Experimental procedure for the preparation of 7-hydroxy-2, 2-dimethylchromane-6-carbaldehyde (20): To a stirred solution of compound $12(2.5 \mathrm{~g}, 12.135 \mathrm{mmol})$ in Acetone ( 25 ml ) were added $\mathrm{K}_{2} \mathrm{CO}_{3}$ ( $5.02 \mathrm{~g}, 36.20 \mathrm{mmol}$ ) and $\mathrm{CH}_{3} \mathrm{I}(1.87 \mathrm{ml}, 29.12 \mathrm{mmol})$ at $0^{\circ} \mathrm{C}$ and stirred at RT for 16 h . The progress of the reaction was monitored by TLC analysis ( $10 \%$ ethyl acetate/pet ether). After completion of the reaction, the reaction mixture was diluted with ethyl acetate ( 250 ml ) and washed with water and brine solution. Organic layer was dried over anhydrous $\mathrm{Na}_{2} \mathrm{SO}_{4}$ and concentrated under reduced pressure to give the crude residue which was charged on silica gel column. The column was eluted with 5\% ethyl acetate/pet ether to give the compound 20 ( $2.4 \mathrm{~g}, 90 \%$ yield).
${ }^{1} \mathrm{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=10.26(\mathrm{~s}, 1 \mathrm{H},-\mathrm{CHO}), 7.59(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.34(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 3.84(\mathrm{~s}$, $3 \mathrm{H},-\mathrm{OCH}_{3}$ ), 2.75-2.72 (t, $J=13.2 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}$ ), 1.83-1.79 (t, $\left.J=14 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right), 1.35(\mathrm{~s}, 6 \mathrm{H}$, $\left.-\left(\mathrm{CH}_{3}\right)_{2}\right)$; MS (ESI): m/z $221(\mathrm{M}+1,100)$.


Experimental procedure for the preparation of (E)-7-methoxy-2, 2-dimethylchromane-6carbaldehyde oxime (21): To a stirred solution of compound 20 ( $2.2 \mathrm{~g}, 10 \mathrm{mmol}$ ) in Methanol and water ( $20: 5 \mathrm{ml}$ ) were added $\mathrm{NH}_{2} \mathrm{OH} . \mathrm{HCl}(820.5 \mathrm{mg}, 11.891 \mathrm{mmol})$ and $\mathrm{Na}_{2} \mathrm{CO}_{3}(1.26 \mathrm{~g}, 11.891 \mathrm{mmol})$ and heated at $90^{\circ} \mathrm{C}$ for 1 h . The progress of the reaction was monitored by TLC analysis ( $20 \%$ ethyl acetate/pet ether). The reaction mixture was concentrated under reduced pressure. Water was added to reaction the mixture, white solid was precipitated. Filtered the precipitate and dried under vacuum to give the compound $21\left(2 \mathrm{~g}, 85 \%\right.$ yield) as off white solid.; ${ }^{1} \mathrm{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta=8.38$ ( s ,
$1 \mathrm{H},-\mathrm{N}=\mathrm{CH}), 7.80(\mathrm{bs}, 1 \mathrm{H},-\mathrm{OH}), 7.38(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 6.33(\mathrm{~s}, 1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), 3.78\left(\mathrm{~s}, 3 \mathrm{H},-\mathrm{OCH}_{3}\right), 2.72-$ $2.69\left(\mathrm{t}, J=13.2 \mathrm{~Hz}, 2 \mathrm{H},-\mathrm{CH}_{2}\right), 1.80-1.77\left(\mathrm{t}, J=13.2 \mathrm{~Hz}, 2 \mathrm{H}, \mathrm{Ar}-\mathrm{CH}_{2}\right), 1.34\left(\mathrm{~s}, 6 \mathrm{H},-\left(\mathrm{CH}_{3}\right)_{2}\right)$; MS (ESI): m/z $236(\mathrm{M}+1,100)$.

GVK-RAG-1-51



GVK-RAG-1-51

(


```
GVK-RAG-1-51
    \bullet
                H
```




GVK-RAG-1-51



GVK BIOSCIENCES PVT. LTD.
MEDICINAL CHEMISTRY LABORATORY - ANALYTICAL RESEARCH LCMS REPORT
===================================================================================================12
Date of Analysis : 6/7/2018 $\quad 7: 09: 28 \mathrm{PM} \quad$ Vial position : P1-B-05
Acq. Method : RND-FA-4.01 MIN Injection Vol : 1.000رl
Sample Name :GVK-RAG-1-51 Instrument ID : ANL-MCL5-LCMS-001

RND-FA 4.01 MIN.M
Column : ACQUITY UPLC BEH C18 ( $50 \mathrm{mmx} 2.1 \mathrm{~mm}, 1.7 \mathrm{~mm}$ )
Mobile Phase: B1: 0.1 \& FA IN WATER A1: 0.18 FA IN ACN
Gradient : Time (min) /8B1: 0/3, 0.3/3, 2.3/98,3.5/98,4/3,4.01/3
Column Flow : $0.6 \mathrm{ml} / \mathrm{min}$
Column Temp : $50^{\circ} \mathrm{C}$


DAD1 A, Sig=215,4 Ref=off

| $\begin{array}{ll} \text { \| Pea\| } & = \\ \text { \|No \| } & \end{array}$ |  | \| | ight | \| Area \& | |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | - |
|  |  |  | I | I | 1 |
| 11 | 12.15 | \| | 9.7221 | 14.9021 | 1.3801 |
| 12 | 12.31 | I | 666.5131 | 1056.928। | 97.9001 |
| 13 | 12.40 |  | 3.5701 | 7.7681 | 0.7201 |

MS Spectrum



GVK-RAG-2-56




 ANL-MCL5-NMR-001


GVK-RAG-2-56



GVK-RAG-2-56






GVK-RAG-2-53





GVK-RAG-2-53

$$
\begin{aligned}
& \tilde{N} \\
& \stackrel{\infty}{\sim} \\
& \stackrel{1}{1}
\end{aligned}
$$

-112.970
$=106.039$
-104.932
-100.225




GVK BIOScience Private Limited
Discovery Chemistry- Analytical Services





Dlotname: 511811N2544-GVK-RRC-1-80_DRORON_01.RRC_plot01

AR MO-NOR/
zeterenca Coas 5181122544-GVZ-PMG-1-80
Solvant: cacl3
Archive directory
/bono/gukb10/data/2018/Wov


10tnama: 511811N2544-GVK-RMC-1-80_DRORON_01.REC_P10t02


GVK-RAG-1-80






GVK-RAG-1-50



GVK-RAG-1-50








D10tnamo: 51180880875-CVK-RMC-1-55p_pROTON_01.REC_plot01



AR NO-NOR/ $18 / 08 / 0071$


Dlotnama: 511808A0875-GVK-RMC-1-55p PROTON 01. HRC plot03


GVx-pac-1-55

trame: 511808A1090-GVK-RAC-1-55_CARGCN_01.REC plot 03
( © SHIMADZU

GVK BIOScience Private Limited
Discovery Chemistry- Analytical Services




AR NO-MOCR/18/08/0376
Reforence Code: 511808A3667-GVK-PAC-1-57
Solvent: cacl3
Archive directory:
/bona/griblo/data/2018/aug
/boma/gviblo/data/2018/hug
Ag11ent
400-MEDD2
Ag11ent $400-$ MEDD2
Data collected on: Nug 32018
Zxpertment: pmorow



Plotnama: 511808n3667-GVK-RMC-1-57_DRORCK_01.ERC_P10t01

AR soc-moxir/18/08/0376
Reterence Code: 511808A3667-CVE-PMC-1-57
solvent: cacl3
Archive directory,
/boma/griblo/data/2018/hug
Ag11ent 400-MEDD2
Data collectad on: Aug 32018

- lo



Dlotname: 511808A3667-GVE-RAG-1-57_DROTCN_01.REC_P10t02

## GVE-RAC-1-57

AR NO-NORP/18/08/0376
Reference Code: 511808A3467-GVZ-PaG-1-57
Solvent: caclu
Archive directory:
/boma/gvib1o/data/2018/hug
Ag1lent 400 - M3DD2
Data collected on: Aug 32018
Data collected on:
Experiment: pronos

Dlotname: 511808A3667-GVK-RAC-1-57 DRORCN 01.REC Plot03



GVK BIOSCIENCES PVT. LTD.
MEDICINAL CHEMISTRY LABORATORY - ANALYTICAL RESEARCH LCMS REPORT




## GVK Biosciences Private Limited Discovery Chemistry - Analytical Services <br> SFC Analytical Chromatogram

User Name: analyst Project Name: 2021\APR-2021\MALLAPUR\ANL-MCL5-SFC-006-APR-2021

| Sample Name: | GVK-RAG-1-57 |  |  |
| :--- | :--- | :--- | :--- |
| Vial: | $1: \mathrm{C}, 1$ | Acquired By: | MLRAnalyst |
| Injection Volume: | 10.00 ul | Sample Set Name: | 19_APRIL_2021 |
| Date Acquired: | 19-Apr-2021 07:42:40 PM IST | Acq. Method Set: | C2_SolvB2_3g_25 |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

SFC Method Conditions

| Column | $:$ CHIRALPAK AD-3 $\left(4.6^{*} 150 \mathrm{~mm}\right) 3 \mu \mathrm{~m}$ |
| :--- | :--- |
| Co-solvent | $:$ Methanol |
| Total flow | $: 3 \mathrm{~g} / \mathrm{min}$ |
| $\%$ of Co-Solvent | $: 25$ |
| ABPR | $: 1500 \mathrm{psi}$ |
| Temperature | $: 30^{\circ} \mathrm{C}$ |



| Peak Results |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  Name RT Area \% Area <br> 1  2.26 2350432 50.01 <br> 2  3.73 2349802 49.99 |  |  |  |  |





## GVK Biosciences Private Limited <br> Discovery Chemistry - Analytical Services

## SFC Analytical Chromatogram

User Name: analyst
Project Name: 2021\APR-2021\MALLAPUR\ANL-MCL5-SFC-006-APR-2021

| Sample Name: | GVK-RAG-1-57-PEAK-1 |  |  |
| :--- | :--- | :--- | :--- |
| Vial: | Acquired By: | MLRAnalyst |  |
| Injection Volume: | 10.00 ul | Sample Set Name: | 17_APRIL_2021 |


| SFC Method Conditions: |  |
| :--- | :--- |
| Column | $:$ CHIRALPAK AD- $3\left(4.6^{*} 150 \mathrm{~mm}\right) 3 \mu \mathrm{~m}$ |
| Co-solvent | $:$ Methanol |
| Total flow | $: 3 \mathrm{~g} / \mathrm{min}$ |
| $\%$ of Co-Solvent | $: 25$ |
| ABPR | $: 1500 \mathrm{psi}$ |
| Temperature | $: 30^{\circ} \mathrm{C}$ |


Peak Results

|  | Name | RT | Area | \% Area |
| :---: | :---: | :---: | :---: | ---: |
| 1 |  | 2.27 | 787603 | 99.90 |
| 2 |  | 4.13 | 801 | 0.10 |

## GVK ${ }^{\text {BlO }}$

Accelerating Research

## GVK-RAG-1-57 PEAK 1

[Data Information]
Creation Date
17-Apr-2021 17:36
[Measurement Information]
Instrument Name POLARIMETER
Model Name P-2000
Serial No. B160661232
Polarizer Dichrom
Faraday Cell Flint Glass

Accessory PTC-262
Accessory S/N C058861481
Temperature
Control Sonsor
Monitor Sensor
Start Mode
25.00 C

Holder
Holder
Start immediately
Light Source WI
Monitor wavelength 589 nm
D.I.T. 5 sec

No. of cycle
Cycle interval 5 sec
Temp. Monitor Holder
Temp. Corr. Factor None
Aperture(S) $\quad 8.0 \mathrm{~mm}$
Aperture(L) Auto
Mode Specific O.R.
Path Length $\quad 50 \mathrm{~mm}$
Concentration $0.2 \mathrm{w} / \mathrm{v} \%$
Water content of sample
[Comment]
Sample name GVK-RAG-1-57 PEAK 1
Comment
User
Division
Company GVK BIO SCIENCES PVT LTD


Factor

|  |  | No. | Sample No. | Mode | Calc. Data | Meas. Data | Monitor(deg) | PMT Voltage[V] |
| :---: | :---: | :---: | :--- | :--- | :---: | :---: | :---: | :---: |
| 1 | ${ }^{*}$ | 1 | GVK-RAG-1-57 PEAK 1-1 | Specific O.R. | -0.9000 | -0.0009 | -0.0015 | 253 |
| 2 | ${ }^{*}$ | 2 | GVK-RAG-1-57 PEAK 1-2 | Specific O.R. | -1.5000 | -0.0015 | -0.0021 | 253 |
| 3 | ${ }^{*}$ | 3 | GVK-RAG-1-57 PEAK 1-3 | Specific O.R. | -1.4000 | -0.0014 | -0.0020 | 253 |
| 4 | ${ }^{*}$ | 4 | GVK-RAG-1-57 PEAK 1-4 | Specific O.R. | -1.1000 | -0.0011 | -0.0017 | 253 |
| 5 | ${ }^{*}$ | 5 | GVK-RAG-1-57 PEAK 1-5 | Specific O.R. | -1.3000 | -0.0013 | -0.0019 | 253 |
| 6 | ${ }^{*}$ | 6 | Avg. |  | -1.2400 |  |  |  |
| 7 |  | 7 | S.D |  | 0.2408 |  |  |  |
| 8 |  | 8 | C.V |  | 19.4219 |  |  |  |


|  | Temperature(C) | Blank | Measurement Date | Comment |
| :--- | :---: | :--- | :--- | :--- |
| 1 | 24.99 | -0.0006 | 17-Apr-2021 17:35 |  |
| 2 | 24.99 | -0.0006 | 17-Apr-2021 17:35 |  |
| 3 | 24.99 | -0.0006 | 17-Apr-2021 17:36 |  |
| 4 | 25.00 | -0.0006 | 17-Apr-2021 17:36 |  |
| 5 | 25.00 | -0.0006 | 17-Apr-2021 17:36 |  |
| 6 |  |  |  |  |
| 7 |  |  |  |  |
| 8 |  |  |  |  |

GVK-REAG-2-57 PEAK 2




## GVK Biosciences Private Limited <br> Empower 3 <br> Discovery Chemistry - Analytical Services <br> <br> SFC Analytical Chromatogram

 <br> <br> SFC Analytical Chromatogram}User Name: analyst Project Name: 2021\APR-2021\MALLAPUR\ANL-MCL5-SFC-006-APR-2021

| Sample Name: | GVK-RAG-1-57-PEAK-2 |  |  |
| :--- | :--- | :--- | :--- |
| Vial: | Acquired By: | MLRAnalyst |  |
| Injection Volume: | 10.00 ul | Sample Set Name: | 17_APRIL_2021 |
| Date Acquired: | 17-Apr-2021 09:53:22 AM IST | Acq. Method Set: | C2_SolvB2_3g_25 |
|  |  |  | Proc. Chnl. Descr.: PDA Spectrum PDA 210.0 nm (PDA |
|  |  |  |  |
|  |  |  |  |


| SFC Method Conditions : |  |
| :--- | :--- |
| Column | $:$ CHIRALPAK AD-3 $\left(4.6^{\star} 150 \mathrm{~mm}\right) 3 \mu \mathrm{~m}$ |
| Co-solvent | $:$ Methanol |
| Total flow | $: 3 \mathrm{~g} / \mathrm{min}$ |
| \% of Co-Solvent | $: 25$ |
| ABPR | $: 1500 \mathrm{psi}$ |
| Temperature | $: 30^{\circ} \mathrm{C}$ |



| Peak Results |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
|  Name RT Area \% Area <br> 1  2.25 876 0.14 <br> 2  3.79 607350 99.86 |  |  |  |  |

## Accelerating Research

## C5748-PEAK 2

[Data Information]
Creation Date 17-Apr-2021 17:49
[Measurement Information]
Instrument Name POLARIMETER
Model Name P-2000
Serial No. B160661232
Polarizer Dichrom
Faraday Cell Flint Glass

Accessory PTC-262
Accessory S/N C058861481
Temperature 25.00 C
Control Sonsor
Monitor Sensor
Start Mode
Holder
Holder
Start immediately
Light Source WI
Monitor wavelength 589 nm
D.I.T. $\quad 5 \mathrm{sec}$

No. of cycle 5
Cycle interval $\quad 5 \mathrm{sec}$
Temp. Monitor Holder
Temp. Corr. Factor None
Aperture(S) $\quad 8.0 \mathrm{~mm}$
Aperture(L) Auto
Mode Specific O.R
Path Length $\quad 50 \mathrm{~mm}$
Concentration $0.2 \mathrm{w} / \mathrm{v} \%$
Water content of sample $0 \%$
Factor
[Comment]
Sample name
Comment
User
Division
Company

C5748-PEAK 2
CONC $=0.2 \%$ in MeOH

GVK BIO SCIENCES PVT LTD

|  |  | No. | Sample No. | Mode | Calc. Data | Meas. Data | Monitor(deg) | PMT Voltage[V] | Temperature(C) |
| :---: | :---: | :---: | :---: | :--- | :---: | :---: | :---: | :---: | :---: |
| 1 | ${ }^{*}$ | 1 | C5748-PEAK 2-1 | Specific O.R. | +1.8000 | +0.0018 | +0.0012 | 263 | 25.00 |
| 2 | ${ }^{*}$ | 2 | C5748-PEAK 2-2 | Specific O.R. | +1.7000 | +0.0017 | +0.0011 | 263 | 25.00 |
| 3 | ${ }^{*}$ | 3 | C5748-PEAK 2-3 | Specific O.R. | +1.9000 | +0.0019 | +0.0013 | 263 | 24.99 |
| 4 | ${ }^{*}$ | 4 | C5748-PEAK 2-4 | Specific O.R. | +1.5000 | +0.0015 | +0.0009 | 263 | 25.00 |
| 5 | ${ }^{*}$ | 5 | C5748-PEAK 2-5 | Specific O.R. | +0.9000 | +0.0009 | +0.0003 | 263 | 25.00 |
| 6 | ${ }^{*}$ | 6 | Avg. |  | +1.5600 |  |  |  |  |
| 7 |  | 7 | S.D |  | 0.3975 |  |  |  |  |
| 8 |  | 8 | C.V |  | 25.4803 |  |  |  |  |


|  | Blank | Measurement Date | Comment |
| :--- | :--- | :--- | :--- |
| 1 | -0.0006 | 17-Apr-2021 17:49 |  |
| 2 | -0.0006 | 17-Apr-2021 17:49 |  |
| 3 | -0.0006 | 17-Apr-2021 17:49 |  |
| 4 | -0.0006 | 17-Apr-2021 17:49 |  |
| 5 | -0.0006 | 17-Apr-2021 17:49 |  |
| 6 |  |  |  |
| 7 |  |  |  |
| 8 |  |  |  |


Reference Code: 511803as655-GVK-RAC-1-33
Solvent: cacl3
Archive alrectory:
/bome/griblo/data/2018/Mar
Agilent 400-Mgind2
Data collected on: Mar 92018
Experiment: Dronor


12


GVX-PAC-1-33
AR $\operatorname{mo}-\mathrm{NORR} / 18 / 03 / 0977$
edb17206003
Reference Code: 511803as655-GVK-RAG-1-33
Solvent: cac13
Archive directory:
/homa/grkb10/đata/2018/Mar
Agilent 400-mgidn
Data collectad on: Mar 22018
Experiment: Dronow


AR No-NORR/18/03/0977
Reference Code: 511803A8655-GVK-RAC-1-33
Solvent: cacl3
Archive alrectory:
/bono/gukb10/đata/2018/Mar
agilent 400-M3DD2
Data collected on: Mar 22018 Experiment: Dronow


12


GVK Biosciences (Pvt.) Ltd.

## Analytical Research and Development

| Data File: | BG_511803A8654 | Sample Name : | P-3323-8-FMC-GVK-G4920-40 |  |
| :--- | :--- | :--- | :--- | :--- |
| Instrument Name: | N/A | Injection Volume $(\mu \mathrm{l}):$ | 2.00 |  |
| Comments: |  | Vial: | GE7 |  |
| Sample Type: | Unknown | Run Time $(\mathrm{min}):$ | 5.01 |  |
| Acquisition Date: | $03 / 09 / 1805: 45: 29 \mathrm{PM}$ |  |  |  |

## LC Method Details

Method : GVK_5MIN; GVK_LCMS_40

Mobile Phase A: $\quad 0.1 \%$ FA in Water
Mobile Phase B: $\quad 0.1 \%$ FA in ACN
Gradient \% of B: $\quad 0 / 80,8 / 80$
Flow
$0.8 \mathrm{ml} / \mathrm{min}$
Column : Acquity UPLC BEH C 18, 2.1*50mm, 1.7 um ,
Column temparature : 40c

| $======-===========$ |  |
| :--- | :--- |
| Detector Type: | PDA |
| Wavelength Range 1 (nm): | N/A |

## UV Chromatogram

RT: $0.00-5.01 \mathrm{SM}$ : 11 G

| Operator: | Thermo Scientific | Page 1 of 1 |
| :--- | :--- | :--- |
| Instrument Name: | N/A | Friday, March 09, 2018, 17:46:04 |



CVE-PAC-1-39
Reterence Code: 511803B3257-GVK-RAG-1-39
Solvent: cac13
Archive directory,
/bome/grib1o/data/2018/4ar
agilent 400-M3DD2
Data collectad on:
zxperiment: phoros
experiment: D3070


GVK- PMC-1-39
AR NO-NOCR/18/03/2066
Reference Code: 511803B8257-GVE-RRC-1-39
Solvent: cac13
Archive directory
/bone/grib1o/data/2018/Ma
Ag11ent 400-MEMD2
Data collected on: Mar 202018
Experiment: pronos


## GVX- $\mathrm{PMC-1-39}$ AR no-NRR/18/03/2066

Reference Code: 511803B3257-GVK-RMG-1-39
Solvent: cacl3
Archive alrectorif
/bome/grib10/đat /2018/Mar
Agilent 400-mzan
Data collected of: Mar 202018
Exper1ment: Dromps


LC/MS REPORT

| Date of Analysis $: 3 / 20 / 2018 \quad$ TIME : $3: 06: 14$ PM  <br> Sample Name GVK-RAG-1-39 <br> Acq. Method : $: \backslash$ CHEM32 $\backslash 1 \backslash$ METHODS $\backslash$ RND-FA-3.2-MIN.M | Vial position: <br> Injection Vol: <br> Instrument Name | P1-A-03 0.300 : ANL-MCL 5 |
| :---: | :---: | :---: |
| Acq Method Conditions : RND-FA-3.2-MIN |  |  |
| Column : Acquity UPLC BEH C18 ( $50 \mathrm{mmx} 2.1 \mathrm{~mm}, 1.7 \mathrm{um}$ ) |  |  |
| Mobile phase:A: 0.1\% of Formic Acid in Water, B: 0.1\% of Formic acid in Acetonitrile |  |  |
| Gradient : Time(min)/ \%B 0/2,0.2/2,1.5/98,2.6/98,2.61/2,3.2/2 |  |  |
| Column temparature : 45 C , Flow rate $: 0.8 \mathrm{ml} / \mathrm{mn}$ |  |  |



MSD1 IIC, MS File




Dlotname: 511803B3301-GVE-RAG-1-35_DRORCN 01.RRC Plote1

AR NO-NORR/18/03/1480
Reference Code: 511803B3301-GVK-RAC-1-35
Solvent: cacl3
Archive a1rectory
/bomo/griblo/data/2018/Mar
Agilent 400-MERD2
Data collected on: Mar 18;201 Experiment: DBOROK




Dlotnama: 511803B3301-GVE-RAC-1-35_DROTOR_01.REC_Plot03

Reference Code: 511803B3301-GVX-RAG-1-35
Solvent: eacl3
Archive directory,
/bome/gvibio/data/2018/Mar
/home/gviblo/data/2
Ag1lent 400 -madD2
Agilent 400-MEDD2
Data collected on: Mar 142018 Experiment: DROMOK




Dlotname: 511803B3301-GVK-RAC-1-35_DRORON_01.REC Plot02

CVI-RAC-1-35-D2OEXC
AR NO-NOR/ $18 / 03 / 1480$
2eference Code: 511803B3301-GVK-EAG-1-35-D2OEXC
Solvent: cacl3
Archive directory,
/boma/griblo/data/2018/Mar
/bome/gribio/data
Data collected on:
Data collected on: Mar 152018
xperiment: pronow



14

GVK Biosciences (Pvt.) Ltd.
Analytical Research and Development

| Data File: | BG_511803B3300 | Sample ID: | GVK-RAG-1-35 |
| :--- | :--- | :--- | :--- |
| Sample Type: | Unknown | Vial: | BA4 |
| Instrument Name: | N/A | Injection Volume $(\mu 1):$ | 2.00 |
| Operator: | Thermo Scientific | Acquisition Date: | $03 / 14 / 1809: 40: 46$ PM |
| Original Data Path: | D:lGVKBIODATAL2018SDATALMA | Run Time(min): | 9.99 |
|  | R-2018511803B3300 |  |  |

## LC Method Details

| Method $:$ | GVK_10MIN |
| :--- | :--- |
| Mobile Phase A: | $0.1 \%$ FA in Water |
| Mobile Phase B: | $0.1 \%$ FA in ACN |
| Gradient \% of B: | $0 / 2,0.5 / 2,9.5 / 98,9.7 / 98,10 / 2$ |
| Flow: | $0.6 \mathrm{ml} / \mathrm{min}$ |
| Column: | BEH C18, 2.1 $* 50 \mathrm{~mm}, 1.7 \mathrm{um}$, |

Detector Type:
Wavelength Range $1(\mathrm{~nm})$ :
UV Chromatogram


| Operator: | Thermo Scientific |
| :--- | :--- |
| Instrument Name: | N/A |

Instrument Name:

Page 1 of 1
Wednesday, March 14, 2018, 21:42:16


Reference Code: 511804C0484-GVK-DRG-1-47D
Solvent: cac13
Arehive directory:
/bomo/grib1o/data/2018/Apr
Agilent 400-MEDD2
Data collectad on: Apr 232018
Experiment: DMOROM

$5 \mathrm{~d} 50677 e 003$

18


## GVI-PRK-A139-4

AR No-/150 $/ 4 / 18 / 2313$
5d50677e003
Reference Code: 511804C0484-GVI-DRG-1-47
Solvent: cac13
Archive directory
/bons/grib1o/data/2018/גpr
/bome/grib1o/data/
Ag11ent 400-MEDD2
Data collectad on:
Experiment: Dsono


CVK_-DRE-K139-45
AR $10-/ 120 R / 4 / 18 / 2311$
zoterence Code: 511804C0484-GVK-PRC-1-47P
Solvent: cac13
archive directory,
bome/gvibio/data/2018/ap
agrlent 400-MEDD2
bata collected on: Apr 232018
Experiment: DMORON


GVK Biosciences (Pvt.) Ltd.
Analytical Research and Development

| Data File: | BG_511804C0483- |
| :--- | :--- |
| Sample Name: |  |
| Instrument Name: | N/A |
| Operator: <br> INSTRUMENT ID: | Thermo Scientific |
|  |  |


| Sample ID: | GVK-RAG-1-47p |
| :--- | :--- |
| Vial: | BC6 |
| Injection Volume $(\mu 1):$ | 1.00 |
| Run Time $(\min ):$ | 5.49 |
| Acquisition Date: | $04 / 23 / 18$ 09:19:06 AM |

LC Method Details

| Method $:$ | GVK_5.5MIN |
| :--- | :--- |
| Mobile Phase A : | $0.1 \%$ FA in Water |

Mobile Phase B : $0.1 \%$ FA in ACN
Gradient $\%$ of B : $0 / 3,0.3 / 3,1.8 / 98,4.5 / 98,4.51 / 3,5.5 / 3$
Flow Rate $\quad: \quad 0.6 \mathrm{ml} / \mathrm{min}$
Column : BEH C18, (2.1*50mm), 1.7 um
Detector Type:
Wavelength Range 1 (nm):
PDA
215.00000

UV Chromatogram
(

Operator:
Instrument Name:

Thermo Scientific N/A

Page 1 of 1
Monday, April 23, 2018, 09:19:39


## cVI-PAC-1-70

AR NO-NORR/18/10/2064
Reference Code: 5115810 2064 -GVK-RNG-1-70
Solvent: cacl3
Archive directory,
/boma/gulb10/data/2018/Oct
Agilent 400 - Mend 2
Data collected on: Oct 122018
Experiment: DMOROM



Dlotname: 5115B1032064-GVK-RAG-1-70_DROTON_01.PRC_plot01

GVE- $\mathrm{PMC}-1-70$
AR MO-MOR/18/10/2064 ee6528f9002
Rolvent: cacl3
Archive directory:
/bomo/gukbio/data/2018/Oct
Agllent 400 - Mend 2
Data collected on: Oct 12 2018
Experiment: DMorow


Dlotnama: 5115810B2064-GVK-RAC-1-70_DROTON_01.RRC_plot02

GVE-PMG-1-70
AR NO-NOR/18/10/2064
Reference Code: 5115810 2064 -GVI-PNG-1-70
Solvent: cacl3
Solvent: cacl3
Archive directory:
/boma/gvib1o/data/2018/Oct
/boma/gukb10/đata/2
Ag11ant $400-$ Msid 2
Ag1lent 400-MEDD2
Data collected on: oct 122018 Data collected on:



GVK BIOSCIENCES PVT. LTD.
MEDICINAL CHEMISTRY LABORATORY - ANALYTICAL RESEARCH LCMS REPORT

```
\begin{tabular}{|c|c|c|c|c|}
\hline Sample Name & : GVK-RAG-1-70 & & Vial position & : P1-C-01 \\
\hline Date of Analysis & : \(10 / 12 / 2018\) & 12:20:50 PM & Injection Vol & :0.300 1 \\
\hline Acq. Method & :RND-FA-4.01 & & Instrument ID & : ANL-MCL5-LCMS-00: \\
\hline
\end{tabular}
RND-FA-4.01 MIN :-
Column : ACQUITY UPLC BEH C18 (50mmx2.1mm, 1.7um)
Mobile Phase : A1 - 0.1 % FA IN WATER ; B1: 0.1%FA IN ACN
Gradient : Time (min) / &B1:0/3,0.3/3,2.3/98,3.5/98,4.0/3,4.01/3
Flow Rate : 0.6 ml/min
Column Temp: 50 % C
```



GVK-RAG-1-7

ANL-MCL5-NMR-004
GVK-RAG-1-76


ANL-MCL5-NMR-004



21



GVK-RAG-1-76
Acq Method Formic Acid_4.0 Min



